

# Silencing of RBP-JK promotes the differentiation of bone marrow mesenchymal stem cells into vascular endothelial cells

ZHENGLIANG LUO<sup>1\*</sup>, YONG DAI<sup>1\*</sup>, MIN CHEN<sup>2</sup>, CHEN ZHU<sup>2</sup>,  
KERONG WU<sup>2</sup>, GUOYUAN LI<sup>2</sup> and XIFU SHANG<sup>2</sup>

<sup>1</sup>Shandong University, Jinan, Shandong 250012; <sup>2</sup>Department of Orthopaedic Surgery, Anhui Provincial Hospital, Hefei, Anhui 230001, P.R. China

Received April 15, 2019; Accepted August 8, 2019

DOI: 10.3892/mmr.2019.10803

**Abstract.** Bone marrow mesenchymal stem cells (BM-MSCs) are important for postnatal angiogenesis and are suitable for use in construction of blood vessels by tissue engineering. The present study aimed to investigate the influence of recombination signal binding protein for immunoglobulin kappa J region (RBP-JK) on the differentiation of BM-MSCs into vascular endothelial cells, and to assess the underlying mechanisms. BM-MSCs were isolated and identified by flow cytometry. Lentiviral vectors encoding RBP-JK shRNA (shRBPJK) were constructed to knockdown RBP-JK expression and endothelial differentiation of BM-MSCs was induced. The experimental groups were treated with: empty lentiviral vector (vector group), growth factors (bFGF and VEGF; induced group), shRBPJK (shRBPJK group), and growth factors + shRBPJK (induced + shRBPJK group). The expression of endothelial markers, vascular endothelial growth factor receptor 2 (Flk-1), and von Willebrand factor (vWF) were detected by immunofluorescence. Additionally, *in vitro* blood vessel formation and phagocytosis were assessed using acetylated LDL, Dil complex and the underlying molecular mechanisms evaluated by western blotting. BM-MSCs were separated and transduced with shRBPJK to reduce RBP-JK expression. Compared with the vector group, the expression of the endothelial cell markers, Flk-1 and vWF, *in vitro* tubule formation, and phagocytosis ability increased, while the expression levels of p-AKT/AKT and p-NF- $\kappa$ B/NF- $\kappa$ B were significantly decreased ( $P < 0.05$ ) in the induced, shRBPJK, and induced + shRBPJK groups. Compared with the induced group, the expression of Flk-1 and vWF, the number of tubules, and phagocytosis were higher

in the induced + shRBPJK group, while the expression levels of p-AKT/AKT and p-NF- $\kappa$ B/NF- $\kappa$ B were lower ( $P < 0.05$ ). Collectively, the present data indicated that silencing of RBP-JK promotes the differentiation of MSCs into vascular endothelial cells, and this process is likely regulated by AKT/NF- $\kappa$ B signaling.

## Introduction

Angiogenesis is necessary for repair of defects in bone tissue. Allogeneic bone or tissue engineered bone transplantation is the most commonly used method used to repair large bone defects (1,2); however, ischemic necrosis often occurs, due to the lack of vascularization in the central part of the tissue, leading to failure of bone defect repair (3).

Bone marrow mesenchymal stem cells (BM-MSCs) are important for postnatal angiogenesis and are suitable for use in tissue engineering to construct blood vessels (4). BM-MSCs are pluripotent adult stem cells, which can be obtained from bone marrow, in addition to hematopoietic stem cells. BM-MSCs originate from bone marrow stromal tissue and participate in the formation of the bone marrow microenvironment. These cells can differentiate into osteocytes, chondrocytes, adipocytes, muscle cells, and fibroblasts in response to different induction conditions *in vitro* (5,6). Furthermore, BM-MSCs can differentiate into vascular components, including vascular endothelial cells and vascular smooth muscle cells (7). *In vivo* and *in vitro* studies have demonstrated that BM-MSCs participate in neovascularization by secreting angiogenic factors (8). Moreover, *in vitro* experiments demonstrate that the combination of vascular endothelial growth factor and basic fibroblast growth factor (bFGF) can induce BM-MSCs to differentiate into endothelial cells and express corresponding cell markers (9).

Recombination signal binding protein for immunoglobulin kappa J region (RBP-JK) is a factor important for induction of MSC proliferation and can also act as an inhibitor of MSC differentiation during development (10). A recent study demonstrated that the Notch signaling pathway is a regulator of bone formation (11). The Notch1 receptor releases the activated intracellular Notch1 domain (N1-ICD/ICN-1) after hydrolysis by  $\gamma$ -secretase. Then, N1-ICD transfers to target genes, including *Mx2*, *HES1*, and *Heyl/2*, in the nucleus and binds

**Correspondence to:** Dr Xifu Shang, Department of Orthopaedic Surgery, Anhui Provincial Hospital, 17 Lujiang Road, Hefei, Anhui 230001, P.R. China  
E-mail: shangxifuchina@163.com

\*Contributed equally

**Key words:** RBP-JK, bone marrow mesenchymal stem cells, endothelial cells

to the transcription inhibitor, RBP-JK (12). The upregulation of target genes is involved in the growth and development of various tissues in embryonic development and during pathological processes in various tissues and organs in adults (13).

In the present study, the effects of silencing of RBP-JK on the differentiation of BM-MSCs into vascular endothelial cells were investigated. The present results provide an experimental basis for the clinical treatment of bone defects using BM-MSCs.

## Materials and methods

**Animals.** Sprague-Dawley specific-pathogen-free (SPF) grade rats (n=20, approximately 120 g, 2-3 weeks old, male) were purchased from Changzhou Cavens Laboratory Animal Co., Ltd., under license No. SCXK (Su) 2016-0010. Rats were housed under SPF conditions, and were automatically maintained at a temperature of  $23^{\circ}\text{C} \pm 2^{\circ}\text{C}$ , a relative humidity of 45-65%, in a controlled 12-h light/dark cycle, and had access to food and water *ad libitum*. All experimental protocols were supervised by the Ethics Committee of Anhui Provincial Hospital (Hefei, China).

**Preparation of BM-MSCs.** Rats were sacrificed by cervical dislocation following anesthesia with isoflurane (5% for induction and 1% for maintenance). When there was no heartbeat, femurs and tibia were collected, immersed in 75% ethanol for 5 min, and adherent muscle tissues were removed by sterile isolation. Bone marrow cavities were exposed, washed repeatedly with PBS, and cell washing solution was collected and screened to form single cell suspensions. Bone marrow cells were collected by centrifugation (870 x g, 5 min). Cells were suspended in DMEM medium (Gibco; Thermo Fisher Scientific, Inc.) containing 10% fetal bovine serum (FBS), inoculated in culture dishes at a density of  $2 \times 10^5/\text{cm}^2$ , and cultured in a  $37^{\circ}\text{C}$   $\text{CO}_2$  incubator. Cell suspensions were then centrifuged at 930 x g for 3 min, and supernatants were discarded. Cell types were detected by flow cytometry using antibodies against CD34 (cat. no. 11-0341-82), CD105 (cat. no. 17-1057-42), and CD90 (cat. no. 14-0900-81, all from Thermo Fisher Scientific, Inc.).

**Construction of the shRBPJK vector.** Three pairs of shRNA oligonucleotides were designed by Shanghai GenePharma Co., Ltd., based on the sequence of the *RBP-JK* gene (Table I).

**Cell transduction.** A PLVshRNA-EGFP (2A) Puro vector (VL3103; Beijing Yingmao Shengye Biotechnology Co., Ltd.) was digested by *Bam*HI/*Eco*RI at  $37^{\circ}\text{C}$ . The shRNA sequences were integrated into the vector according to the protocol: Pre-denaturation at  $95^{\circ}\text{C}$  for 5 min,  $84^{\circ}\text{C}$  for 5 min,  $74^{\circ}\text{C}$  for 5 min and  $72^{\circ}\text{C}$  for 5 min, and then maintenance at  $4^{\circ}\text{C}$ . Lentiviruses encoding shRBPJK were established as previously described (14). At 60% confluence, cells were transduced with the aforementioned lentiviruses (Shanghai GenePharma Co. Ltd.) encoding shRBPJK ( $1 \times 10^6$  IFU/PFU/ml) or empty vector (Shanghai GenePharma Co. Ltd.) using Polybrene (Invitrogen; Thermo Fisher Scientific, Inc.). Twenty-four hours after transduction, the medium was replaced with fresh DMEM, and cells were incubated in a  $\text{CO}_2$  incubator (5%  $\text{CO}_2$ )

at  $37^{\circ}\text{C}$  for 48 h. RBP-JK mRNA and protein expression were detected by quantitative real-time PCR and western blotting, respectively.

**Quantitative real-time polymerase chain reaction (qRT-PCR).** Cells were seeded in 6-well plates. After transduction for 48 h, mRNA was extracted using a TRIzol assay kit (Baosheng Science & Technology Innovation Co, Ltd.). According to the kit instructions, mRNA was transcribed into cDNA (cat. no. 639522, Takara Biotechnology Co., Ltd.) and fluorescence quantitative PCR was used to determine the expression levels of targeted genes, using cDNA as a template. The expression levels of *RBP-JK* were normalized to those of *GAPDH*. Primers are listed in Table II. Reactions included 9.5  $\mu\text{l}$  RNase-free  $\text{dH}_2\text{O}$ , 1  $\mu\text{l}$  cDNA/DNA, 2  $\mu\text{l}$  primers, and 12.5  $\mu\text{l}$  2X UltraSYBR Mixture, and were conducted using the following temperature cycles:  $95^{\circ}\text{C}$  (denaturation) 10 sec,  $56^{\circ}\text{C}$  (annealing) 30 sec, and  $72^{\circ}\text{C}$  (extension) 30 sec, for 40 cycles.

**Experimental groups.** Cells were divided into four experimental groups, treated with: i) Lentiviral vector only (vector group), ii) growth factors (10 ng/ml bFGF + 50 ng/ml VEGF; induced group), iii) lentivirus encoding RBP-JK-targeting shRNA (shRBPJK group), and iv) growth factors + lentivirus encoding shRBPJK (induced + shRBPJK group). For growth factor induction, the original culture medium was discarded and the induction solution (DMEM + FBS + 10 ng/ml bFGF + 50 ng/ml VEGF) was added to the BM-MSCs, as previously described (9). The induction solution was changed every three days for ten consecutive days. Rat bFGF (cat. no. P1020-500) and rat VEGF (cat. no. CJ96) were purchased from Novoprotein.

**Immunofluorescence.** The cells were fixed using 4% poly-formaldehyde (PFA) for 15 min, washed with PBS three times for 3 min each, and permeated with 0.5% Triton X-100 at room temperature for 20 min. Cells were then blocked with 5% BSA at  $37^{\circ}\text{C}$  for 30 min, followed by the addition of primary antibodies and incubation overnight at  $4^{\circ}\text{C}$ . Primary antibodies were Flk-1 (1:500; cat. no. bs-10412R; Bioss Antibodies, Inc.) and von Willebrand factor (vWF) (1:400; product code ab6994; Abcam). After washing in PBS, fluorescent secondary antibody Cy3 (1:200, BA1032, Wuhan Boster Biological Technology, Ltd.) was added and cells were incubated at  $37^{\circ}\text{C}$  for 30 min. Samples were then incubated with DAPI for 5 min to stain the nuclei.

**In vitro angiogenesis assay.** Matrix glue (250  $\mu\text{l}$ ) was added into each well of a 24-well plate and uniformly distributed. Cells were starved for 2 h in serum-free medium and BM-MSCs digested and resuspended at a density of  $5 \times 10^5/\text{ml}$ . Aliquots of cell suspensions (10  $\mu\text{l}$ ) were added to each well. The time until tube formation was monitored and images were captured using a microscope (BX51; Olympus Corporation).

**Phagocytosis of acetylated LDL, Dil complex.** Acetylated LDL, Dil complex (Dil-ac-LDL) was added into M199 medium containing 10% FBS to a final concentration of 10  $\mu\text{g}/\text{ml}$  to assess phagocytosis. After culture for 24 h to allow cell adherence, Dil-ac-LDL was added to each experimental group and

Table I. Sequences of shRBPJK.

shRBPJK	Sequence (5'-3')
shRBPJK-F1	GATCCGCAAGCGGATAAAGGTCATCTCTTCCTGTCAGAAGATGACCTTTATCCGCTTGCTTTTTTG
shRBPJK-R1	AATTCAAAAAGCAAGCGGATAAAGGTCATCTTCTGACAGGAAGAGATGACCTTTATCCGCTTGCG
shRBPJK-F2	GATCCGCACTCCCAAGACTGATAATTCTTCCTGTCAGAAATTATCAGTCTTGGGAGTGCTTTTTTG
shRBPJK-R2	AATTCAAAAAGCACTCCCAAGACTGATAATTTCTGACAGGAAGAATTATCAGTCTTGGGAGTGCG
shRBPJK-F3	GATCCGCCGAAACAATGTACAGATGTCTTCCTGTCAGAACATCTGTACATTGTTTCGGCTTTTTTG
shRBPJK-R3	AATTCAAAAAGCCGAAACAATGTACAGATGTTCTGACAGGAAGACATCTGTACATTGTTTCGGCG

shRBPJK, RBP-JK shRNA; F, forward; R, reverse.

Table II. Primer sequences.

Genes	Sequence (5'-3')	Primer length (bp)	Product length (bp)	Annealing (°C)
<i>RBP-JK</i> F	CTTAGCAAGCGGATAAAGGTC	21	386	58
<i>RBP-JK</i> R	TTGTGGAGTTGTGATACAGGGT	22		
<i>GAPDH</i> F	GCAAGTTCAACGGCACAG	18	141	58.6
<i>GAPDH</i> R	CGCCAGTAGACTCCACGAC	19		

*RBP-JK*, recombination signal binding protein for immunoglobulin kappa J region; F, forward; R, reverse.




Figure 1. Identification of BM-MSCs. The majority of cells were CD90<sup>+</sup> CD105<sup>+</sup> CD34<sup>-</sup>. BM-MSCs, bone marrow mesenchymal stem cells.

cells were then incubated at 37°C, in 5% CO<sub>2</sub>, for 24 h, washed twice with PBS, fixed in 4% PFA, and observed under a fluorescence microscope (BX51).

**Western blotting.** After transduction and/or induction, proteins were extracted from cells for western blotting using a ReadyPrep protein isolation kit (GE Healthcare Life Sciences). Extracted proteins were quantified with a bicinchoninic acid protein assay kit and separated by 12% SDS-PAGE (25 µg/lane). After transferring onto nitrocellulose membranes, the membranes were blocked with 5% skimmed milk. Membranes were then

incubated with mouse monoclonal anti-GAPDH (1/2,000; TA-08; ZS-BIO; OriGene Technologies, Inc.), rabbit monoclonal anti-RBP-JK (1/5,000; product code ab180588, Abcam), anti-AKT (1/5,000; cat. no. 4691, CST), anti-p-AKT (1/5,000; cat. no. 9271, CST), anti-NF-κB (1/5,000; cat. no. 6956; CST), or anti-p-NF-κB (1/1,000; cat. no. sc-136548; Santa Cruz Biotechnology, Inc.) overnight at 4°C. Secondary antibody (1/1,000; product code ab131368, Abcam) was then added and incubated for 1-2 h at room temperature. ECL exposure liquid droplets (cat. no. RPN2133; GE Healthcare Life Sciences) were then added to the membranes. Finally, the membranes were




Figure 2. Verification of the interference effect of shRBPJK. (A) RBP-JK mRNA levels. (B) RBP-JK protein levels. shRBPJK2 had the optimal influence on the expression of RBP-JK. Upper panel: Representative blots. Lower panel: quantification data. \* $P < 0.05$ , compared with the control group. RBP-JK, recombination signal binding protein for immunoglobulin kappa J region; shRBPJK, RBP-JK shRNA.

exposed using a gel imaging system (Bio-Rad Laboratories, Inc.). Grayscale density of bands was analyzed using Quantity One analysis software v1.4.6 (Bio-Rad Laboratories, Inc.).

**Statistical analysis.** Data are presented as the means and standard deviation, and were analyzed using SPSS 17.0 (SPSS, Inc.). The significance of differences was evaluated using a one-way ANOVA with post-hoc Newman-Keuls test, and  $P$ -values  $< 0.05$  were considered to indicate a statistically significant difference.

## Results

**Isolation and identification of BM-MSCs.** The results of isolation and identification of BM-MSCs are presented in Fig. 1.

The majority of isolated cells were  $CD90^+$   $CD105^+$   $CD34^-$ , indicating that they were BM-MSCs.

**Detection of RBP-JK knockdown.** The results of fluorescence quantitative PCR (Fig. 2A) and western blotting (Fig. 2B) revealed that RBP-JK expression was significantly lower in cells treated with shRBPJK2 than that in the control group ( $P < 0.05$ ); therefore, shRBPJK2 was selected for use in subsequent experiments.

**shRBPJK promotes the expression of endothelial cell markers.** The expression levels of the endothelial cell markers, Flk-1 and vWF, were significantly higher in the induced and shRBPJK groups than that in the vector control group ( $P < 0.05$ ). In addition, the expression levels of Flk-1 and vWF were significantly higher in the induced + shRBPJK group than those in the induced group ( $P < 0.05$ ) (Fig. 3).

**shRBPJK promotes angiogenesis in vitro.** The results of *in vitro* angiogenesis assays are presented in Fig. 4. Compared with the vector control group, the numbers of tubes in all other groups were significantly greater ( $P < 0.05$ ). Furthermore, relative to the induced group, the number of tubes was significantly increased in the induced + shRBPJK group ( $P < 0.05$ ).

**shRBPJK promotes Dil-ac-LDL phagocytosis.** Endothelial cells can mediate phagocytosis of ac-LDL, by binding to scavenger receptors on their surface, while LDL receptors distributed on other cells cannot ingest ac-LDL (15); therefore, in an attempt to identify vascular endothelial cells, their ability to absorb Dil-ac-LDL was assessed. The results of the Dil-ac-LDL phagocytosis assay are presented in Fig. 5. Compared with the vector control group, the positive rate of low density lipoprotein phagocytosis was significantly increased in all other groups ( $P < 0.05$ ). Furthermore, compared with the induced group, the rate of phagocytosis was significantly higher in the induced + shRBPJK group ( $P < 0.05$ ).

**shRBPJK reduces phosphorylation of AKT and NF- $\kappa$ B.** Compared with the vector control group, levels of p-AKT/AKT and p-NF- $\kappa$ B/NF- $\kappa$ B were significantly decreased in all other groups ( $P < 0.05$ ). Furthermore, compared with the induced group, the expression levels of p-AKT/AKT and p-NF- $\kappa$ B/NF- $\kappa$ B were significantly lower in the induced + shRBPJK group ( $P < 0.05$ ) (Fig. 6).

## Discussion

In the present study, evidence was generated that silencing of RBP-JK not only promotes the differentiation of MSCs into vascular endothelial cells, but also facilitates VEGF- and bFGF-induced endothelial differentiation. Moreover, the present data demonstrated that this effect may be regulated by the AKT/NF- $\kappa$ B signaling pathway.

The repair of bone defects using allogeneic or tissue engineered bone depends on the establishment of close spatial and temporal connections between blood vessels and bone cells; hence, angiogenesis is fundamental to the process of bone healing. Therefore, methods to promote angiogenesis and reconstruct local blood supply, as soon as possible




Figure 3. The expression of endothelial cell surface markers. (A) Representative images of Flk-1 and vWF expression. Left panel: Flk-1 expression. Right panel: vWF expression. (B) Quantification data for Flk-1 and vWF expression. \* $P < 0.05$ , compared with the vector control group; \*\* $P < 0.05$ , compared with the induced group. Scale bars, 100  $\mu\text{m}$ . Flk-1, vascular endothelial growth factor receptor 2; vWF, von Willebrand factor; shRBPJK, RBP-JK shRNA.




Figure 4. Results of *in vitro* angiogenesis assay. Upper panel: representative images. Lower panel: Quantification data. \* $P < 0.05$ , compared with the vector control group; \*\* $P < 0.05$ , compared with the induced group. Scale bars, 100  $\mu\text{m}$ . shRBPJK, RBP-JK shRNA.

Figure 5. Dil-ac-LDL phagocytosis assay. Upper panel: representative images. Lower panel: Quantification data. \* $P < 0.05$ , compared with the vector control group; \*\* $P < 0.05$ , compared with the induced group. Scale bars, 100  $\mu\text{m}$ . shRBPJK, RBP-JK shRNA.




Figure 6. Expression of AKT, p-AKT, NF- $\kappa$ B, and p-NF- $\kappa$ B. (A) Representative blots. (B) Quantification data for p-AKT/AKT. (C) Quantification data for p-NF- $\kappa$ B/NF- $\kappa$ B. \* $P < 0.05$ , compared with the vector control group; # $P < 0.05$ , compared with the induced group. shRBPJK, RBP-JK shRNA.

after allogeneic bone or tissue engineered bone implantation into bone defects, are currently of particular research interest (16). MSCs can be induced to transform into vascular endothelial cells and smooth muscle cells (17). Furthermore, human BM-MSCs cultured *in vitro* can differentiate into endothelial-like cells after 7 days of induction in medium containing VEGF and bFGF (18); the induced cells express the endothelial surface markers, Flk-1 (KDR), Flt-1, and vWF, and exhibit *in vitro* angiogenesis ability (19). MSCs transplanted into animals differentiate into endothelial cells and smooth muscle cells, participate in angiogenesis, and improve blood supply (20). In the present study, MSCs were isolated and identified by flow cytometry; resulting in cells that were CD90<sup>+</sup> CD105<sup>+</sup> CD34<sup>-</sup>, indicating that the isolated cells were BM-MSCs. The prepared BM-MSCs were used to determine the effects of RBP-JK silencing on endothelial differentiation.

RBP-JK protein is expressed in MSCs and has an important role in their proliferation (21). In the present study, RBP-JK was knocked down in BM-MSCs. Factors commonly used to induce the differentiation of MSCs into endothelium *in vitro* include VEGF, bFGF, insulin-like growth factor, and transforming growth factor- $\beta$ , among others. (22). As the most important cytokine in vascular endothelial cells, VEGF functions to increase capillary permeability, promote endothelial cell proliferation, and induce angiogenesis (23). In the present study, a combination of VEGF and bFGF was used to induce MSC differentiation into endothelial cells. The present results revealed that the expression of the endothelial markers, Flk-1 and vWF, on the cell surface were increased,

both after induction with 50 ng/ml VEGF and 10 ng/ml bFGF and by RBP-JK silencing. Moreover, RBP-JK silencing further promoted the endothelial differentiation induced by 50 ng/ml VEGF and 10 ng/ml bFGF. These results indicated that the transformation of BM-MSCs into endothelial cells can be induced by knocking down RBP-JK, and that there is a synergistic effect of induction using growth factors and knockdown of RBP-JK.

The number of tubules generated was increased by growth factor-induced endothelial differentiation and by silencing of RBP-JK, and there was a synergistic effect between growth factor-induction and shRBP-JK silencing. These results indicated that knocking down RBP-JK can promote endothelial mitosis, induce the formation of new vascular networks, and has an important role in the differentiation and proliferation of endothelial cells. Endothelial cells can proliferate, and form new blood vessel networks *in vitro* and *in vivo* (24,25). In addition, the present study revealed that both growth factor induction and shRBPJK could increase the ability of cells to phagocytose ac-LDL, and that these two methods had a synergistic effect. These results indicated that the ability to take up ac-LDL is another method that can be used to identify endothelial cells.

NF- $\kappa$ B is a key factor involved in the regulation of cellular gene transcription and is activated by oxygen free radicals (26). Upon activation, the transcription of NF- $\kappa$ B p65 and NF- $\kappa$ B P50 increase, and the transcription and protein expression of various proinflammatory factors are elevated, resulting in enhanced cell adhesion, inflammation, cell differentiation, and



degradation of the extracellular matrix (27). AKT has an important role in the structure and function of endothelial cells (28). In addition, AKT can phosphorylate a series of nuclear factors to induce the release of NF- $\kappa$ B and regulate gene transcription (29,30). The present study revealed that levels of p-AKT and p-NF- $\kappa$ B decreased after growth factor-induced endothelial differentiation and knocking down RBP-JK, and that this decrease was more significant when endothelial induction and RBP-JK silencing were performed simultaneously. The AKT/NF- $\kappa$ B signaling pathway is also related to endothelial differentiation (31), and the present results indicated that RBP-JK-induced endothelial cell formation and angiogenesis may be mediated by AKT/NF- $\kappa$ B signaling.

There are still some limitations to the present study. On the one hand, although the molecular mechanisms underlying the differentiation of bone marrow mesenchymal stem cells into vascular endothelial cells were revealed, the application of RBP-JK modified MSCs in animals with bone defect still requires confirmation. On the other hand, how Akt/NF- $\kappa$ B signaling pathway is involved in the process requires more elucidation.

In conclusion, the silencing of RBP-JK promotes differentiation of MSCs into vascular endothelial cells, and is likely regulated by the AKT/NF- $\kappa$ B signaling pathway.

#### Acknowledgements

Not applicable.

#### Funding

The present study was supported by the Provincial Natural Science Foundation of Anhui (grant no. 1808085QH242).

#### Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

#### Authors' contributions

ZL, YD, MC, CZ, KW, GL and XS performed the experiments and analyzed the data. ZL and YD designed the study and wrote the manuscript. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

#### Ethics approval and consent to participate

All animal procedures were approved by the Ethics Committee of Anhui Provincial Hospital (Hefei, China).

#### Patient consent for publication

Not applicable.

#### Competing interests

The authors declare that they have no competing interests.

#### References

- Wang W and Yeung KWK: Bone grafts and biomaterials substitutes for bone defect repair: A review. *Bioact Mater* 2: 224-247, 2017.
- Henkel J, Woodruff MA, Epari DR, Steck R, Glatt V, Dickinson IC, Choong PF, Schuetz MA and Hutmacher DW: Bone regeneration based on tissue engineering conceptions-A 21st century perspective. *Bone Res* 1: 216-248, 2013.
- Socie G, Selimi F, Sedel L, Frija J, Devergie A, Esperou Bourdeau H, Ribaud P and Gluckman E: Avascular necrosis of bone after allogeneic bone marrow transplantation: Clinical findings, incidence and risk factors. *Br J Haematol* 86: 624-628, 1994.
- Bing W, Pang X, Qu Q, Bai X, Yang W, Bi Y and Bi X: Simvastatin improves the homing of BMSCs via the PI3K/AKT/miR-9 pathway. *J Cell Mol Med* 20: 949-961, 2016.
- Zheng H, Zou W, Shen J, Xu L, Wang S, Fu YX and Fan W: Opposite effects of coinjection and distant injection of mesenchymal stem cells on breast tumor cell growth. *Stem Cells Transl Med* 5: 1216-1228, 2016.
- Bianco P, Robey PG and Simmons PJ: Mesenchymal stem cells: Revisiting history, concepts, and assays. *Cell Stem Cell* 2: 313-319, 2008.
- Kang ML, Kim JE and Im GI: Vascular endothelial growth factor-transfected adipose-derived stromal cells enhance bone regeneration and neovascularization from bone marrow stromal cells. *J Tissue Eng Regen Med* 11: 3337-3348, 2017.
- Zou D, Zhang Z, He J, Zhang K, Ye D, Han W, Zhou J, Wang Y, Li Q, Liu X, *et al*: Blood vessel formation in the tissue-engineered bone with the constitutively active form of HIF-1 $\alpha$  mediated BMSCs. *Biomaterials* 33: 2097-2108, 2012.
- Cao Y, Sun Z, Liao L, Meng Y, Han Q and Zhao RC: Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo. *Biochem Biophys Res Commun* 332: 370-379, 2005.
- Wang YC, Wang SH, Wei YN, Du DW, Xu H, Gao CC, Zheng MH, Xie J, Li JC, Dong GY, *et al*: Notch-RBP-J signaling is required by bone marrow stromal cells for the treatment of acute graft versus host disease. *Stem Cell Res* 11: 721-735, 2013.
- Lee SY and Long F: Notch signaling suppresses glucose metabolism in mesenchymal progenitors to restrict osteoblast differentiation. *J Clin Invest* 128: 5573-5586, 2018.
- Blain J, Bedard J, Thompson M, Boisvert FM and Boucher MJ: C-terminal deletion of NOTCH1 intracellular domain (N1<sup>ICD</sup>) increases its stability but does not amplify and recapitulate N1<sup>ICD</sup>-dependent signalling. *Sci Rep* 7: 5034, 2017.
- Yu L, Liang H, Lu Z, Zhao G, Zhai M, Yang Y, Yang J, Yi D, Chen W, Wang X, *et al*: Membrane receptor-dependent Notch1/Hes1 activation by melatonin protects against myocardial ischemia-reperfusion injury: In vivo and in vitro studies. *J Pineal Res* 59: 420-433, 2015.
- Xu W, Cao J, Zhou Y, Wang L and Zhu G: GPR30 activation improves memory and facilitates DHPG-induced LTD in the hippocampal CA3 of middle-aged mice. *Neurobiol Learn Mem* 149: 10-19, 2018.
- Sharma D, Hamlet SM, Petcu EB and Ivanovski S: The effect of bisphosphonates on the endothelial differentiation of mesenchymal stem cells. *Sci Rep* 6: 20580, 2016.
- Xie C, Reynolds D, Awad H, Rubery PT, Pelled G, Gazit D, Guldberg RE, Schwarz EM, O'Keefe RJ and Zhang X: Structural bone allograft combined with genetically engineered mesenchymal stem cells as a novel platform for bone tissue engineering. *Tissue Eng* 13: 435-445, 2007.
- Zhu F, Guo GH, Chen W and Wang NY: Effects of bone marrow-derived mesenchymal stem cells engraftment on vascular endothelial cell growth factor in lung tissue and plasma at early stage of smoke inhalation injury. *World J Emerg Med* 1: 224-228, 2010.
- Adibfar A, Amoabediny G, Baghaban Eslaminejad M, Mohamadi J, Bagheri F and Zandieh Doulabi B: VEGF delivery by smart polymeric PNIPAM nanoparticles affects both osteogenic and angiogenic capacities of human bone marrow stem cells. *Mater Sci Eng C Mater Biol Appl* 93: 790-799, 2018.
- Cattaneo F, Castaldo M, Parisi M, Faraonio R, Esposito G and Ammendola R: Formyl peptide receptor 1 modulates endothelial cell functions by NADPH Oxidase-dependent VEGFR2 transactivation. *Oxid Med Cell Longev* 2018: 2609847, 2018.

20. Wang H, Ding XG, Yang JJ, Li SW, Zheng H, Gu CH, Jia ZK and Li L: LncRNA MIAT facilitated BM-MSCs differentiation into endothelial cells and restored erectile dysfunction via targeting miR-200a in a rat model of erectile dysfunction. *Eur J Cell Biol* 97: 180-189, 2018.
21. Shang X, Luo Z, Wang X, Jaeblo T, Marymont JV and Dong Y: Deletion of RBPIK in mesenchymal stem cells enhances osteogenic activity by Up-regulation of BMP signaling. *PLoS One* 10: e0135971, 2015.
22. Dalley A, Smith JM, Reilly JT and Neil SM: Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: Evidence for a role of extracellular calmodulin in fibroblast proliferation. *Br J Haematol* 93: 856-862, 1996.
23. Adini A, Adini I, Chi ZL, Derda R, Birsner AE, Matthews BD and D'Amato RJ: A novel strategy to enhance angiogenesis in vivo using the small VEGF-binding peptide PR1P. *Angiogenesis* 20: 399-408, 2017.
24. Staton CA, Reed MW and Brown NJ: A critical analysis of current in vitro and in vivo angiogenesis assays. *Int J Exp Pathol* 90: 195-221, 2009.
25. Jin K, Li B, Lou L, Xu Y, Ye X, Yao K, Ye J and Gao C: In vivo vascularization of MSC-loaded porous hydroxyapatite constructs coated with VEGF-functionalized collagen/heparin multilayers. *Sci Rep* 6: 19871, 2016.
26. Long L, Pang XX, Lei F, Zhang JS, Wang W, Liao LD, Xu XE, He JZ, Wu JY, Wu ZY, *et al*: SLC52A3 expression is activated by NF- $\kappa$ B p65/Rel-B and serves as a prognostic biomarker in esophageal cancer. *Cell Mol Life Sci* 75: 2643-2661, 2018.
27. Zhu L, Chen T, Chang X, Zhou R, Luo F, Liu J, Zhang K, Wang Y, Yang Y, Long H, *et al*: Salidroside ameliorates arthritis-induced brain cognition deficits by regulating Rho/ROCK/NF- $\kappa$ B pathway. *Neuropharmacology* 103: 134-142, 2016.
28. Ou HC, Chou WC, Chu PM, Hsieh PL, Hung CH and Tsai KL: Fucoxanthin protects against oxLDL-induced endothelial damage via activating the AMPK-Akt-CREB-PGC1 $\alpha$  pathway. *Mol Nutr Food Res* 63: e1801353, 2019.
29. Kalantary-Charvadeh A, Sanajou D, Hemmati-Dinarvand M, Marandi Y, Khojastehfard M, Hajipour H, Mesgari-Abbasi M, Roshangar L and Nazari Soltan Ahmad S: Micheliolide protects against doxorubicin-induced cardiotoxicity in mice by regulating PI3K/Akt/NF- $\kappa$ B signaling pathway. *Cardiovasc Toxicol* 19: 297-305, 2019.
30. Song Z, Chen H, Xu W, Wu S and Zhu G: Basolateral amygdala calpain is required for extinction of contextual fear-memory. *Neurobiol Learn Mem* 155: 180-188, 2018.
31. Cho JS, Kang JH, Park IH and Lee HM: Steroids inhibit vascular endothelial growth factor expression via TLR4/Akt/NF- $\kappa$ B pathway in chronic rhinosinusitis with nasal polyp. *Exp Biol Med* (Maywood) 239: 913-921, 2014.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.